HC Wainwright Reiterates Buy Rating for Black Diamond Therapeutics (NASDAQ:BDTX) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,350,000 shares, an increase of 12.8% from the October 15th total of 2,970,000 shares. Approximately 9.8% of the shares of the company are short sold. […]
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023.
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 2,970,000 shares, an increase of 24.3% from the September 30th total of 2,390,000 shares. Approximately 8.7% of the shares of the company are short sold. […]
/PRNewswire/ - Diamond Therapeutics Inc. ("Diamond"), a clinical-stage drug development company focused on non-hallucinogenic, psychedelic-based therapies for.